These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 23272673)

  • 21. Importance of delivered cycles and nomogram for intraperitoneal chemotherapy in ovarian cancer.
    Yen MS; Twu NF; Lai CR; Horng HC; Chao KC; Juang CM
    Gynecol Oncol; 2009 Sep; 114(3):415-9. PubMed ID: 19577277
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An Unusual Intra-abdominal Inflammatory Reaction to Intraperitoneal Chemotherapy.
    Lee S
    Minn Med; 2015 Aug; 98(8):37-8. PubMed ID: 26455037
    [No Abstract]   [Full Text] [Related]  

  • 23. Quality of life evaluations in patients with ovarian cancer during chemotherapy treatment.
    Le T; Leis A; Pahwa P; Wright K; Ali K; Reeder B; Hopkins L; Fung MF
    Gynecol Oncol; 2004 Mar; 92(3):839-44. PubMed ID: 14984950
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Randomized study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group comparing quality of life in patients with ovarian cancer treated with cisplatin/paclitaxel versus carboplatin/paclitaxel.
    Greimel ER; Bjelic-Radisic V; Pfisterer J; Hilpert F; Daghofer F; du Bois A;
    J Clin Oncol; 2006 Feb; 24(4):579-86. PubMed ID: 16446330
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intraperitoneal chemotherapy for ovarian cancer.
    Ozols RF; Bookman MA; Young RC
    N Engl J Med; 2006 Apr; 354(15):1641-3; author reply 1641-3. PubMed ID: 16611959
    [No Abstract]   [Full Text] [Related]  

  • 26. Should intraperitoneal chemotherapy be considered as standard first-line treatment in advanced stage ovarian cancer?
    Petignat P; du Bois A; Bruchim I; Fink D; Provencher DM
    Crit Rev Oncol Hematol; 2007 May; 62(2):137-47. PubMed ID: 17188887
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Quality of life in ovarian cancer patients receiving chemotherapy.
    Lakusta CM; Atkinson MJ; Robinson JW; Nation J; Taenzer PA; Campo MG
    Gynecol Oncol; 2001 Jun; 81(3):490-5. PubMed ID: 11371144
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intraperitoneal chemotherapy comes of age.
    Cannistra SA
    N Engl J Med; 2006 Jan; 354(1):77-9. PubMed ID: 16394306
    [No Abstract]   [Full Text] [Related]  

  • 29. Feasibility of intraperitoneal chemotherapy in advanced epithelial ovarian cancer.
    Maheshwari A; Gupta S; Prabhash K; Tongaonkar HB
    Indian J Cancer; 2010; 47(2):225-6. PubMed ID: 20448394
    [No Abstract]   [Full Text] [Related]  

  • 30. Assessment of factors that contribute to decreased quality of life in Gynecologic Oncology Group ovarian cancer trials.
    Lorusso D; Mainenti S; Ferrandina G; Scambia G
    Expert Rev Anticancer Ther; 2010 Jul; 10(7):987-91. PubMed ID: 20645686
    [No Abstract]   [Full Text] [Related]  

  • 31. Quality of life in ovarian cancer patients: comparison of paclitaxel plus cisplatin, with cyclophosphamide plus cisplatin in a randomized study.
    Bezjak A; Tu D; Bacon M; Osoba D; Zee B; Stuart G; Roy JA; Piccart M; Eisenhauer E
    J Clin Oncol; 2004 Nov; 22(22):4595-603. PubMed ID: 15466785
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intraperitoneal chemotherapy for ovarian cancer: 2009 goals.
    Walker JL
    Gynecol Oncol; 2009 Mar; 112(3):439-40. PubMed ID: 19245944
    [No Abstract]   [Full Text] [Related]  

  • 33. The feasibility of carboplatin-based intraperitoneal chemotherapy in ovarian cancer.
    Kim SW; Paek J; Nam EJ; Kim SH; Kim JH; Kim YT
    Eur J Obstet Gynecol Reprod Biol; 2010 Oct; 152(2):195-9. PubMed ID: 20576343
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reversible posterior leukoencephalopathy syndrome following intravenous paclitaxel and intraperitoneal cisplatin chemotherapy for fallopian tube cancer.
    Onujiogu N; Lengyel E; Yamada SD
    Gynecol Oncol; 2008 Dec; 111(3):537-9. PubMed ID: 18554701
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Patients' preferences for therapy in advanced epithelial ovarian cancer: development, testing, and application of a bedside decision instrument.
    Elit LM; Levine MN; Gafni A; Whelan TJ; Doig G; Streiner DL; Rosen B
    Gynecol Oncol; 1996 Sep; 62(3):329-35. PubMed ID: 8812525
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intraperitoneal drug delivery for ovarian cancer: why, how, who, what, and when?
    Echarri Gonzalez MJ; Green R; Muggia FM
    Oncology (Williston Park); 2011 Feb; 25(2):156-65, 170. PubMed ID: 21456387
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase 1/pharmacology study of intraperitoneal topotecan alone and with cisplatin: potential for consolidation in ovarian cancer.
    Andreopoulou E; Chen T; Liebes L; Curtin J; Blank S; Wallach R; Hochster H; Muggia F
    Cancer Chemother Pharmacol; 2011 Aug; 68(2):457-63. PubMed ID: 21069334
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intraperitoneal chemotherapy for advanced epithelial ovarian malignancy: lessons learned.
    Bunting M; Chan W; Brand A; Blomfield P
    Aust N Z J Obstet Gynaecol; 2009 Dec; 49(6):667-71. PubMed ID: 20070720
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A phase II study of intraperitoneal cisplatin and thiotepa in residual ovarian carcinoma: a Gynecologic Oncology Group study.
    Feun LG; Blessing JA; Major FJ; DiSaia PJ; Alvarez RD; Berek JS
    Gynecol Oncol; 1998 Dec; 71(3):410-5. PubMed ID: 9887240
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer.
    Alberts DS; Liu PY; Hannigan EV; O'Toole R; Williams SD; Young JA; Franklin EW; Clarke-Pearson DL; Malviya VK; DuBeshter B
    N Engl J Med; 1996 Dec; 335(26):1950-5. PubMed ID: 8960474
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.